Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...

Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain ...

Vor Bio appoints Dallan Murray as chief commercial officer, leveraging his extensive experience to drive commercialization ...

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...

In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...

BACK TO CBER — Dr. Vinay Prasad has returned to the FDA’s Center for Biologics Evaluation and Research, leaving industry and ...

Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At ...

If you purchased or acquired securities in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your ...